Breaking News Instant updates and real-time market news.

BIDU

Baidu

$221.64

5.97 (2.77%)

, OXY

Occidental Petroleum

$69.74

-0.13 (-0.19%)

12:56
02/13/18
02/13
12:56
02/13/18
12:56

Notable companies reporting after market close

Notable companies reporting after the market close, with earnings consensus, include Baidu (BIDU), consensus $2.10... Occidental Petroleum (OXY), consensus 41c... MetLife (MET), consensus 86c... DaVita (DVA), consensus 94c... Diamondback Energy (FANG), consensus $1.51... Bioverativ (BIVV), consensus 89c... Western Union (WU), consensus 45c... Voya Financial (VOYA), consensus 71c... Neurocrine Biosciences (NBIX), consensus 18c... Twilio (TWLO), consensus (6c).

BIDU

Baidu

$221.64

5.97 (2.77%)

OXY

Occidental Petroleum

$69.74

-0.13 (-0.19%)

MET

MetLife

$44.60

-0.025 (-0.06%)

DVA

DaVita

$73.29

-0.12 (-0.16%)

FANG

Diamondback Energy

$116.01

5.5 (4.98%)

BIVV

Bioverativ

$103.60

0.55 (0.53%)

WU

Western Union

$19.76

-0.01 (-0.05%)

VOYA

Voya Financial

$47.65

-0.42 (-0.87%)

NBIX

Neurocrine

$82.17

2.89 (3.65%)

TWLO

Twilio

$26.11

0.32 (1.24%)

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 26

    Feb

  • 08

    Mar

  • 25

    Apr

  • 30

    May

  • 12

    Jun

BIDU Baidu
$221.64

5.97 (2.77%)

01/29/18
NOMU
01/29/18
DOWNGRADE
Target $276
NOMU
Neutral
Nomura downgrades Baidu to Neutral after 50% share rally
Nomura Instinet analyst Jialong Shi downgraded Baidu to Neutral from Buy and cut his price target for the shares to $276 from $301. The stock in afternoon trading is down 2% to $254.88. The analyst lowered his fiscal 2018 estimates by 8% to reflect Baidu's ramp-up in spending to acquire user traffic and video content. He believes the stock's 50% rise over the past 12 months largely prices in the company's positive developments. Shi prefers shares of Tencent (TCEHY) at current valuation levels.
01/29/18
NOMU
01/29/18
DOWNGRADE
NOMU
Neutral
Baidu downgraded to Neutral from Buy at Nomura Instinet
02/05/18
OTRG
02/05/18
DOWNGRADE
OTRG
Mixed
Baidu downgraded to Mixed from Positive at OTR Global (pre-open)
Pre-open, OTR Global downgraded Baidu to Mixed from Positive following checks indicating search growth came under pressure in Q4 2017 and was lower than expectations due to budget shifts towards ecommerce and social media platforms.
01/23/18
JEFF
01/23/18
DOWNGRADE
Target $285
JEFF
Hold
Jefferies wants better entry point, downgrades Baidu to Hold
Jefferies analyst Karen Chan downgraded Baidu (BIDU) to Hold from Buy and lowered her price target for the shares to $285 from $291. The Chinese technology company closed yesterday down $1.64 to $254.34. The analyst says that while she remains positive on Baidu's "leading" artificial intelligence position, she prefers to wait for a better entry point following the stock's rebound from lows. In China Internet, Chan's top picks are Tencent (TCEHY), Alibaba (BABA) and Weibo (WB). Momo (MOMO) remains the analyst's preferred mid-cap pick.
OXY Occidental Petroleum
$69.74

-0.13 (-0.19%)

01/17/18
MACQ
01/17/18
INITIATION
Target $75
MACQ
Neutral
Occidental Petroleum initiated with a Neutral at Macquarie
Macquarie analyst Kate Sloan initiated Occidental Petroleum with a Neutral and $75 price target. Sloan said Occidental has a high break-even and does not cover its dividend at current oil forecasts.
01/22/18
SBSH
01/22/18
UPGRADE
Target $73
SBSH
Neutral
Occidental Petroleum upgraded to Neutral from Sell at Citi
Citi analyst Robert Morris upgraded Occidental Petroleum (OXY) to Neutral and raised his price target for the shares to $73 from $64. The upgrades follows the analyst's estimate increases last week. His highest conviction pair trade into Q4 earnings is long Occidental versus Hess Corp. (HES). He expects Hess to miss on production and to lower its 2018 guidance due to shut-ins in the deepwater Gulf of Mexico and weather-related issues in the Bakken. Occidental, on the other hand, is "hitting on all cylinders," Morris writes.
01/04/18
BOFA
01/04/18
DOWNGRADE
Target $80
BOFA
Neutral
Occidental Petroleum downgraded to Neutral on valuation at BofA/Merrill
As previously reported, BofA/Merrill downgraded Occidental Petroleum to Neutral from Buy and increased its price target to $80 from $79. Analyst Doug Leggate said the strong recovery in shares appropriately values lower US corporate taxes in its domestic Chemicals and midstream business.
01/04/18
BOFA
01/04/18
DOWNGRADE
BOFA
Neutral
Occidental Petroleum downgraded to Neutral from Buy at BofA/Merrill
MET MetLife
$44.60

-0.025 (-0.06%)

01/02/18
DBAB
01/02/18
INITIATION
Target $55
DBAB
Hold
MetLife initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Joshua Shanker started MetLife with a Hold rating and $55 price target. The analyst sees limited share upside until the company can generate a consistency of earnings growth.
01/31/18
GSCO
01/31/18
DOWNGRADE
Target $57
GSCO
Buy
MetLife downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman analyst Alex Scott removed MetLife from the Conviction Buy List due to ongoing uncertainty from an expanded reserve review following the announcement it will incur a $525M-$575M charge. The analyst said there is potential for further reserve action resulting in earnings risk driven by lower potential capital deployment due to the risk of MetLife halting share repurchases. Scott maintains a Buy rating on MetLife and a $57 price target on shares.
01/19/18
SBSH
01/19/18
NO CHANGE
Target $63
SBSH
Buy
Citi removes Voya Financial, adds Prudential to Focus List
Citi analyst Suneet Kamath removed Voya Financial (VOYA) from his firm's Focus List saying the sale of its Annuity operation, a significant positive catalyst, is largely reflected in the valuation. The analyst keeps a Buy rating on the shares with a $63 price target. Kamath added Prudential (PRU) to the Focus List and keeps a Buy rating on the shares with a $130 price target. He believes the company could replace MetLife (MET) as the "default, large-cap life insurer in the space for investors to own." The analyst keeps a Sell rating on MetLife with a $48 price target.
01/31/18
01/31/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Market Perform from Outperform at BMO Capital with analyst Tim Long saying that while the press has recently speculated about the order cuts for iPhone X, which he says reflects his first quarter model for a "weaker mix," he is "more concerned by a secular change" for the iPhone product. AK Steel (AKS) downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners saying AK Steel's "disappointing" first quarter and normalized earnings guidance is due to management's "commodity neutral approach," which limits benefits from higher steel prices. 3. U.S. Bancorp (USB) downgraded to Underweight from Neutral at JPMorgan with analyst Vivek Juneja saying the benefit from tax cuts and improving consumer spending are likely to be offset by increased tech spending. 4. Wayfair (W) downgraded to Accumulate from Buy at Gordon Haskett analyst Chuck Grom saying he believes it is important to remain disciplined with the stock at an all-time high, though Grom notes the rating change should not be interpreted as a concern for near-term sales trends, which he believes appear strong. 5. MetLife (MET) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Alex Scott citing ongoing uncertainty from an expanded reserve review following the announcement it will incur a $525M-$575M charge. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DVA DaVita
$73.29

-0.12 (-0.16%)

01/04/18
BOFA
01/04/18
UPGRADE
BOFA
Buy
DaVita upgraded to Buy from Neutral at BofA/Merrill
01/11/18
BOFA
01/11/18
NO CHANGE
Target $92
BOFA
Buy
DaVita price target raised to $92 from $85 at BofA/Merrill
BofA/Merrill analyst Kevin Fischbeck raised DaVita's price target to $92 from $85 and reiterated a Buy rating on a stabilizing commercial outlook with potential share repurchase upside. Fischbeck raised estimates to reflect tax reform, the Davita Medical Group sale, and capital deployment.
01/12/18
BARD
01/12/18
NO CHANGE
Target $95
BARD
Outperform
DaVita price target raised to $95 from $82 at Baird
Baird analyst Whit Mayo raised his price target on DaVita to $95 from $82 based on tax reform and its stock buyback pushing its earning higher. He said DaVita remains a Best Idea for 2018 as he sees core EBITDA growth inflecting into 2019 and diminishing CPA-related risks. Mayo reiterated his Outperform rating on DaVta shares.
01/04/18
BOFA
01/04/18
UPGRADE
BOFA
Buy
DaVita upgraded to Buy, named a Top Pick at BofA/Merrill
BofA/Merrill analyst Kevin Fischbeck upgraded DaVita to Buy from Neutral, named its a Top Pick, and raised its price target to $85 from $75. Fischbeck thinks DaVita's commercial mix and pricing are stabilizing, which could prove to be a tailwind given conservative initial guidance, and the sale of DaVita Medical Group proceeds can be used for share repurchases, investments, and debt repayment. Further, the analyst sees upside from the shift to MA, tax reform, and EPO savings.
FANG Diamondback Energy
$116.01

5.5 (4.98%)

02/01/18
DBAB
02/01/18
INITIATION
Target $162
DBAB
Buy
Diamondback Energy initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Nitin Kumar started Diamondback Energy with a Buy rating and $162 price target.
02/01/18
DBAB
02/01/18
INITIATION
DBAB
Deutsche names Parsley, Diamondback, Cimarex top E&P picks
Deutsche analyst Nitin Kumar rolled out coverage on 17 stocks in the U.S. Exploration & Production after the close today. His top picks are Parsley Energy (PE), Diamondback Energy (FANG) and Cimarex Energy (XEC).
01/23/18
FBCO
01/23/18
NO CHANGE
Target $143
FBCO
Outperform
Diamondback Energy price target raised to $143 from $123 at Credit Suisse
Credit Suisse analyst Betty Jiang raised her price target for Diamondback Energy to $143 from $123 on valuation. The analyst reiterates an Outperform rating on the shares.
02/06/18
RILY
02/06/18
INITIATION
Target $150
RILY
Neutral
Diamondback Energy initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Rehan Rashid started Diamondback Energy with a Neutral rating and $150 price target.
BIVV Bioverativ
$103.60

0.55 (0.53%)

01/23/18
MSCO
01/23/18
UPGRADE
Target $105
MSCO
Equal Weight
Bioverativ upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison upgraded Bioverativ (BIVV) to Equal Weight after the company announced a deal to be acquired by Sanofi (SNY) for $105 per share in cash.
01/24/18
ARGS
01/24/18
DOWNGRADE
ARGS
Hold
Bioverativ downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Bioverativ (BIVV) to Hold from Buy after the company announced a deal to be acquired by Sanofi (SNY) for $105 per share in cash. Hellweg says the strong run-up in the stock and the forthcoming acquisition have fully valued the stock at current levels.
01/24/18
FBCO
01/24/18
NO CHANGE
Target $105
FBCO
Neutral
Bioverativ price target raised to $105 from $65 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Bioverativ (BIVV) to $105 from $65 ahead of likely closing of the Sanofi (SNY) deal. The analyst reiterates a Neutral rating on Bioverativ's shares.
01/22/18
JEFF
01/22/18
DOWNGRADE
Target $105
JEFF
Hold
Bioverativ downgraded to Hold from Buy at Jefferies
Jefferies analyst Eun Yang downgraded Bioverativ (BIVV) while raising her price target for the shares to $105 from $79 following the takeover by Sanofi (SNY). The analyst views the potential for a counterbid as unlikely given the "quite healthy" deal premium and potential synergy with Sanofi pipeline.
WU Western Union
$19.76

-0.01 (-0.05%)

01/08/18
01/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Technologies (UTX) upgraded to Buy from Neutral at Goldman Sachs with analyst Noah Poponak saying he believes United Technologies is within the year of maximum new engine loss on Geared Turbofan engines, or GTFs, and thinks the market will begin to look beyond that peak loss and give increased consideration to substantial longer-term cash flows. 2. Caterpillar (CAT) upgraded to Overweight from Neutral at JPMorgan with analyst Ann Duignan saying she believes the stock still has "significant upside" despite the outperformance in 2017. 3. Flir Systems (FLIR) upgraded to Buy from Hold at SunTrust with analyst Michael Ciarmoli citing the company's realigned segment structure under the new management team with a sharper focus on the larger government and industrial end-markets, forecasting outperformance driven by RAID order flow and new Department of Defense procurement initiatives. 4. Applied Materials (AMAT) upgraded to Strong Buy from Buy at Needham with analyst Y. Edwin Mok saying he is positive on the company's "balanced WFE exposure across segments" amid the likelihood of moderating NAND growth. 5. Western Union (WU) upgraded to Neutral from Negative at Susquehanna with analyst James Friedman saying he believes the company may be working with Ripple Labs to potentially implement blockchain applications in remittance and sees that as a possible accelerator with business-to-business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/18
SUSQ
01/08/18
UPGRADE
Target $21
SUSQ
Neutral
Western Union upgraded to Neutral at Susquehanna
As previously reported, Susquehanna analyst James Friedman upgraded Western Union to Neutral from Negative. He believes the company may be working with Ripple Labs to potentially implement blockchain applications in remittance and sees that as a possible accelerator with business-to-business. Friedman raised his price target to $21 from $17 on Western Union shares.
01/08/18
SUSQ
01/08/18
UPGRADE
SUSQ
Neutral
Western Union upgraded to Neutral from Negative at Susquehanna
12/14/17
12/14/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CBS (CBS) initiated with an Overweight at Stephens. 2. Floor & Decor (FND) initiated with a Buy at Stifel. 3. Tronox (TROX) initiated with an Overweight at Barclays. 4. LivePerson (LPSN) initiated with a Buy at B. Riley FBR. 5. Western Union (WU) assumed with a Sell at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
VOYA Voya Financial
$47.65

-0.42 (-0.87%)

01/22/18
WELS
01/22/18
NO CHANGE
WELS
Outperform
Voya has other potential suitors, selloff unwarranted, says Wells Fargo
Wells Fargo analyst Sean Dargan does not think AIG's (AIG) acquisition today of Validus (VR) warrants a selloff in Voya Financial (VOYA) shares. Earlier this month, media reports indicated AIG was in talks to acquire Voya but that the talks broke down in November over price. There are other potential buyers for Voya's "go-forward business mix of investment management, retirement and group benefits," Dargan tells investors in a research note. One potential party that might be interested in Voya is Nippon Life of Japan, who publicly proclaimed a strategy of international acquisitions, the analyst contends. Dargan has an Outperform rating on Voya shares.
01/09/18
WELS
01/09/18
DOWNGRADE
Target $79
WELS
Market Perform
Principal Financial downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Sean Dargan downgraded Principal Financial to Market Perform with a $79 price target saying he now prefers Voya Financial (VOYA). After shedding its capital-intensive annuity businesses, Voya should look more like Principal over time, Dargan tells investors in a research note. He sees more upside in Voya at current valuation levels.
01/09/18
EVER
01/09/18
NO CHANGE
EVER
Evercore ISI says reported AIG interest a 'pretty bullish signal' for Voya value
After Bloomberg said that AIG (AIG) had previously held talks to acquire Voya Financial (VOYA) in a deal valued at more than $10B, Evercore ISI analyst Thomas Gallagher said he reads this as a sign that AIG is open to large scale M&A and as "a pretty bullish signal" for the private market value of Voya being considerably above its current share price.
NBIX Neurocrine
$82.17

2.89 (3.65%)

01/05/18
JEFF
01/05/18
NO CHANGE
Target $105
JEFF
Buy
Neurocrine price target raised to $105 from $81 at Jefferies
Jefferies analyst Biren Amin raised his price target for Neurocrine Biosciences (NBIX) to $105 following his fourth proprietary survey on tardive dyskinesia. The respondents provided bullish estimates compared to past surveys, which sees prescribing possibly doubling from current levels for Neurocrine's Ingrezza and Teva's (TEVA) Austedo in both mod-severe and mild Tardive Dyskinesia by the end of 2018, Amin tells investors in a research note. The analyst expects Ingrezza to lead Austedo in market share raised his revenue estimates for Neurocrine. Amin keeps a Buy rating on the shares.
01/22/18
OPCO
01/22/18
NO CHANGE
OPCO
Neurocrine, CymaBay could benefit from increased M&A, says Oppenheimer
Oppenheimer analyst Jay Olson notes that driven by tax reform and cash repatriation, Biotech investors expect increased M&A activity. The analyst believes tax reform with cash repatriation will increase firepower of potential buyers, and points out that managements stated interest in targets with strategic fit. In his coverage universe, Olson believes Neurocrine (NBIX), Portola Pharmaceuticals (PTLA) and CymaBay (CBAY) shares could benefit from increased M&A based on their therapeutic areas and strategic fit.
01/16/18
OPCO
01/16/18
NO CHANGE
Target $95
OPCO
Outperform
Neurocrine price target raised to $95 from $85 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Neurocrine to $95 from $85 based on preliminary Q4 results increasing his revenue and earnings estimates. The analyst reiterates an Outperform rating on the shares.
01/16/18
NEED
01/16/18
NO CHANGE
Target $95
NEED
Buy
Neurocrine price target raised to $95 from $86 at Needham
Needham analyst Alan Carr raised his price target on Neurocrine Biosciences to $95 after the company pre-announced 2017 revenue and INGREZZA sales last week. The analyst says the above-estimate print was in part the result of a delay in the uptake of the 80mg capsule that is less expensive than the 40mg. Carr believes that the launch is proceeding well, warranting an increase in FY18 revenue while raising his 2018-2020 INGREZZA sales forecast to $350M from $340M. The analyst keeps his Buy rating on Neurocrine Biosciences.
TWLO Twilio
$26.11

0.32 (1.24%)

01/18/18
KEYB
01/18/18
NO CHANGE
KEYB
Cost savings emerge as 'killer app' for artificial intelligence, says KeyBanc
Over the past 35 days, KeyBanc analyst Brent Bracelin hosted meetings at Adobe (ADBE), Autodesk (ADSK), Algorithmia, Cloudera (CLDR), Coupa (COUP), Facebook (FB), Guidewire (GWRE), Netflix (NFLX), NVIDIA (NVDA), Salesforce (CRM), SAP, Synopsys (SNPS), Twilio (TWLO), Tableau (DATA), Talend (TLND), Veeva (VEEV), Workday (WDAY), and Zendesk (ZEN) as part of an AI & Cloud-themed field trip. The analyst notes that cost savings have emerged as the "killer app" for artificial intelligence, and large enterprise interest in migrating back-office apps to cloud has been slow, but is picking up, conversational AI and bot activity is yielding real cost savings. Further, Bracelin sees 2018 as a defining year for enterprise AI applications, and is most impressed by enterprise AI initiatives at Microsoft (MSFT), Zendesk, Guidewire, and Adobe.
12/06/17
BARD
12/06/17
NO CHANGE
Target $37
BARD
Outperform
Twilio investor day tone positive, says Baird
Baird analyst William Power said the overall tone of Twilio's investor day was positive. He said he remains positive on the company's competitive position and long-term growth opportunity fueled by increasing cloud communications use cases. He also remains positive on its stronger revenue growth and ability to improve margins long term. Power reiterated his Outperform rating and $37 price target on Twilio shares.
09/27/17
NORL
09/27/17
NO CHANGE
Target $9.5
NORL
Outperform
Vonage, Twilio enable Amazon's PinPoint text messaging, says Northland
Amazon (AMZN) announced yesterday that it has added two-way text messaging to its Pinpoint customer engagement service, which leverages the company's simple notification service, or SNS, capabilities, Northland analyst Michael Latimore tells investors in a research note. Vonage (VG) and Twilio (TWLO) enable SNS and thus, the Pinpoint customer engagement text messaging service, Latimore writes. He notes that Vonage also partners with Amazon on Chime conferencing and Essentials. The analyst has an Outperform rating on Vonage with a $9.50 price target. The stock in early trading is up 24c to $8.13.
09/27/17
OPCO
09/27/17
NO CHANGE
OPCO
Outperform
Twilio should be bought on weakness, says Oppenheimer
Oppenheimer analyst Ittai Kidron notes that Amazon's (AMZN) AWS has announced the addition of global two-way text messaging capabilities to Pinpoint, its suite of user communication tools. The analyst believes investor fears that this will compete with Twilio (TWLO) are incorrect. While there is no "Powered by Twilio" branding, AWS's new Pinpoint SMS capability is powered on the back-end by Twilio's platform, he contends, noting the close relationship that Twilio has with AWS. Given Twilio's presence behind the scenes, Kidron would view the announcement as a positive for Twilio and would be aggressive buyers on any weakness. He reiterates an Outperform rating on Twilio's shares.

TODAY'S FREE FLY STORIES

COTV

Cotiviti Holdings

09:22
02/23/18
02/23
09:22
02/23/18
09:22
Recommendations
Cotiviti Holdings analyst commentary  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REI

Ring Energy

09:22
02/23/18
02/23
09:22
02/23/18
09:22
Syndicate
Ring Energy 5.36M share Spot Secondary priced at $14.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CHK

Chesapeake

09:21
02/23/18
02/23
09:21
02/23/18
09:21
Recommendations
Chesapeake analyst commentary  »

Little in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LKQ

LKQ Corp.

$40.05

-1.53 (-3.68%)

09:21
02/23/18
02/23
09:21
02/23/18
09:21
Recommendations
LKQ Corp. analyst commentary  »

LKQ shares have 32%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

, SPX

S&P 500

09:20
02/23/18
02/23
09:20
02/23/18
09:20
Technical Analysis
Technical Take: S&P 500 potential bullish pattern update »

In a note yesterday we…

SPY

SPDR S&P 500 ETF Trust

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLF

Cleveland-Cliffs

09:19
02/23/18
02/23
09:19
02/23/18
09:19
Upgrade
Cleveland-Cliffs rating change  »

Cleveland-Cliffs upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRIM

Northrim BanCorp

$33.50

-0.05 (-0.15%)

09:19
02/23/18
02/23
09:19
02/23/18
09:19
Hot Stocks
Northrim BanCorp raises quarterly dividend by 9% to 24c per share »

Northrim BanCorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
02/23/18
02/23
09:18
02/23/18
09:18
Options
Overnight activity included 97 trades in SPX and 14 trades in VIX »

97 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUN

Huntsman

, KBR

KBR

09:17
02/23/18
02/23
09:17
02/23/18
09:17
Hot Stocks
On The Fly: Pre-market Movers »

UP AFTER EARNINGS:…

HUN

Huntsman

KBR

KBR

CNK

Cinemark

ASIX

AdvanSix

ETR

Entergy

ABR

Arbor Realty

RHP

Ryman Hospitality

BUFF

Blue Buffalo Pet Products

$34.12

-0.68 (-1.95%)

GIS

General Mills

OLED

Universal Display

$154.90

-0.7 (-0.45%)

ACIA

Acacia Communications

$41.84

-1.6 (-3.68%)

WING

Wingstop

$46.78

1.05 (2.30%)

ZOES

Zoe's Kitchen

RDFN

Redfin

$21.57

0.27 (1.27%)

INTU

Intuit

$172.10

-1.22 (-0.70%)

FSLR

First Solar

$66.28

-0.42 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 04

    Mar

  • 05

    Mar

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 15

    Mar

  • 29

    Mar

  • 03

    May

  • 23

    May

  • 14

    Jun

  • 25

    Jun

AROC

Archrock

09:16
02/23/18
02/23
09:16
02/23/18
09:16
Upgrade
Archrock rating change  »

Archrock upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGI

UGI Corporation

09:16
02/23/18
02/23
09:16
02/23/18
09:16
Hot Stocks
UGI Corporation names Ted Jastrzebski CEO »

UGI Corporation has named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLESY

Lendlease Group

$13.60

0.15 (1.12%)

09:16
02/23/18
02/23
09:16
02/23/18
09:16
Conference/Events
Lendlease Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

CVX

Chevron

09:15
02/23/18
02/23
09:15
02/23/18
09:15
Upgrade
Chevron rating change  »

Chevron upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 27

    Mar

TTD

Trade Desk

$48.40

-1.41 (-2.83%)

09:15
02/23/18
02/23
09:15
02/23/18
09:15
Recommendations
Trade Desk analyst commentary  »

Trade Desk strong Q4 and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNGN

Financial Engines

$29.95

-0.45 (-1.48%)

09:13
02/23/18
02/23
09:13
02/23/18
09:13
Upgrade
Financial Engines rating change  »

William Blair upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$135.24

14.89 (12.37%)

09:13
02/23/18
02/23
09:13
02/23/18
09:13
Recommendations
Zebra Technologies analyst commentary  »

Zebra Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 30

    May

WING

Wingstop

$46.78

1.05 (2.30%)

09:11
02/23/18
02/23
09:11
02/23/18
09:11
Recommendations
Wingstop analyst commentary  »

Wingstop model intact…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$351.58

-0.53 (-0.15%)

09:09
02/23/18
02/23
09:09
02/23/18
09:09
Recommendations
CoStar Group analyst commentary  »

CoStar Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    May

TSS

TSYS

$86.80

0.24 (0.28%)

, MA

MasterCard

$172.95

0.63 (0.37%)

09:08
02/23/18
02/23
09:08
02/23/18
09:08
Hot Stocks
Netspend, MLB partner for team-branded GPR prepaid cards »

Prepaid card provider…

TSS

TSYS

$86.80

0.24 (0.28%)

MA

MasterCard

$172.95

0.63 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 08

    Mar

HMSY

HMS Holdings

$15.32

-0.06 (-0.39%)

09:06
02/23/18
02/23
09:06
02/23/18
09:06
Earnings
Breaking Earnings news story on HMS Holdings »

HMS Holdings reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

AABA

Altaba

$75.52

0.41 (0.55%)

09:06
02/23/18
02/23
09:06
02/23/18
09:06
Recommendations
Altaba analyst commentary  »

Altaba price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

AMZN

Amazon.com

$1,485.34

2.42 (0.16%)

09:05
02/23/18
02/23
09:05
02/23/18
09:05
Upgrade
Amazon.com rating change  »

Amazon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

GTLS

Chart Industries

$55.85

6.14 (12.35%)

09:05
02/23/18
02/23
09:05
02/23/18
09:05
Recommendations
Chart Industries analyst commentary  »

Chart Industries target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

PFE

Pfizer

$35.74

-0.02 (-0.06%)

09:04
02/23/18
02/23
09:04
02/23/18
09:04
Hot Stocks
Pfizer announces positive CHMP opinion for MYLOTARG, BOSULIF »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 04

    Apr

KZIA

Kazia Therapeutics

$4.99

0.43 (9.43%)

09:04
02/23/18
02/23
09:04
02/23/18
09:04
Hot Stocks
Kazia Therapeutics confirms FDA Orphan Designation for GDC-0084 »

Kazia Therapeutics is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.